57th ASH Annual Meeting and Exposition (December 5-8, 2015): 332. Antithrombotic Therapy: Poster I

Antithrombotic Therapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Management of Cancer-Associated Upper Extremity Deep Vein Thrombosis with and without Venous Catheters at a Tertiary Care Center

Said Y. ALKindi, MD, ARCPath^1,2, Chatree Chai-Adisaksopha, MD^3,4, Matthew Cheah⁵^* and Lori Ann Linkins, MD, MSc, FRCPC³^*

¹Department of Medicine - Division of Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada
²Ministry Of Health, AL Khuweir, Oman
³Department of Medicine, McMaster University, Hamilton, ON, Canada
⁴Medicine, Chiang Mai University, Chiang Mai, Thailand
⁵McMaster University, Hamilton, ON, Canada

1120

Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis

Chatree Chai-Adisaksopha, MD^1,2, Matthew Cheah³^*, Said Y. ALKindi, MD, ARCPath^4,5, Alfonso Iorio, MD, PhD³, Mark A. Crowther, MD, MSc, FRCPC⁶ and Lori Ann Linkins, MD, MSc, FRCPC⁷^*

¹Department of Medicine, McMaster University, Hamilton, ON, Canada
²Medicine, Chiang Mai University, Chiang Mai, Thailand
³McMaster University, Hamilton, ON, Canada
⁴Department of Medicine - Division of Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada
⁵Ministry Of Health, AL Khuweir, Oman
⁶St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada
⁷Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada

1121

Comparing the Efficacy of Aspirin or Low Molecular Weight Heparin or Vitamin K Antagonists in the Risk of Thromboembolic Events in Patients with Multiple Myeloma Treated with Lenalidomide-Based Therapy

Martha L Louzada, BSc, MD, MSc¹, Maria-Victoria Mateos²^*, Lenicio Siqueira, BSc³^*, Jose-Maria B Bermejo, MD, phD⁴^*, Enrique M Ocio⁵^* and Jose-Ramon Porras, MD⁴^*

¹Department of Medicine, Division of Hematology, University of Western Ontario, London, ON, Canada
²Hematology, University Hospital of Salamanca, Salamanca, Spain
³Department of Medicine, Division of Hematology, University of Western ontario, London, ON, Canada
⁴University of Salamanca, Salamanca, Spain
⁵Centro de Investigación del Cancer Universidad de Salamanca-CSIC, Salamanca, Spain

1122

Improving Outcomes and Reducing Costs for Cancer Associated Thrombosis Using a Centralized Service: The Cleveland Clinic Experience

Emma Rabinovich¹^*, Shiva Shrotriya²^*, Keith R. McCrae, MD^2,3, John R. Bartholomew, MD⁴, Bernard J. Silver, MD⁵, Kristine Adams²^* and Alok A. Khorana, MD⁶

¹Case Western Reserve School of Medicine, Cleveland, OH
²Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³Taussig Cancer Institute and Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
⁴The Cleveland Clinic, Cleveland, OH
⁵Department of Hematologic Oncology and Blood disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁶Cleveland Clinic, Cleveland, OH

1123

Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOAC) Versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboembolism: A Retrospective Analysis

Jeremy A Ross, MD¹^*, Marilyn Miller, MSN-RN, FNP-C²^* and Cristhiam M Rojas Hernandez, MD³

¹Internal Medicine, The University of Texas Health Science Center, Houston, TX
²Thrombosis and Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
³Thrombosis and Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston

1124

Clopidogrel Treatment Is Associated with a Decrease in Cancer Incidence

Avi Leader, MD^1,2^*, Ravit Zelikson-Saporta^2,3^*, Uri Rozovski, MD^2,4^*, David Pereg, MD^2,5^*, Pia Raanani, MD^2,4, Galia Spectre, MD PhD⁴^*, Michael Lishner, MD^2,3 and Doron Hermoni, MD^2,6^*

¹Division of Hematology, Davidoff Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel
²Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
³Department of Medicine A, Meir Medical Center, Kfar Saba, Israel
⁴Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
⁵Department of Cardiology, Meir Medical Center, Kfar Saba, Israel
⁶Department of Family Medicine, Sharon-Shomron District, Clalit Health Services, Netanya, Israel

1125

Outcome of Noac Exposure during Pregnancy (...and the problem of event reporting...)

Jan Beyer-Westendorf, MD, Sandra Marten, MD^* and Franziska Michalski, MD^*

Vascular Medicine, Dresden University Hospital, Dresden, Germany

1126

Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?

Alex C. Spyropoulos, MD¹^*, Ron Preblick, PharmD, MPH²^*, Jackie Kwong, PhD²^*, Melissa Lingohr-Smith, PhD³^* and Jay Lin, PhD, MBA³^*

¹Department of Hospital Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY
²Daiichi Sankyo, Inc., Parsippany, NJ
³Novosys Health, Green Brook, NJ

1127

Pattern and Management of Intracranial Haemorrhage with Rivaroxaban or Dabigatran Compared to Vitamin K Antagonists - Results of the Prospective Dresden Noac Registry

Sandra Marten, MD^*, Luise Tittl, B.Sc.^*, Katharina Daschkow^* and Jan Beyer-Westendorf, MD

Vascular Medicine, Dresden University Hospital, Dresden, Germany

1128

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Markus Honickel, MD¹^*, Joanne van Ryn, PhD² and Oliver Grottke, MD PhD¹^*

¹Department of Anesthesiology, RWTH University Hospital Aachen, Aachen, Germany
²CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

1129

Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial

Alma R. Oskarsdottir, BS¹^*, Brynja R. Gudmundsdottir, MS¹^*, Olafur S. Indridason, MD, MPH¹^*, Hulda M. Jensdottir, BS¹^*, David O. Arnar, MD, PhD¹^*, Einar S. Bjornsson, MD, PhD^1,2^*, Magnus K. Magnusson, MD^1,2^*, Sigrun H. Lund, PhD²^*, Brynjar Vidarsson, MD¹^*, Charles W. Francis, MD³ and Pall T. Onundarson, MD²

¹Landspitali National University Hospital, Reykjavik, Iceland
²Faculty of Medicine, University of Iceland School of Health Sciences, Reykjavik, Iceland
³University of Rochester Medical Center, Rochester, NY

1130

Efficacy and Safety of Weight-Adjusted Extended Duration Tinzaparin for Prevention of Post-Operative Venous Thromboembolism after Bariatric Surgery

Deborah M. Siegal, MD, MSc¹, Pankaj Handa, MD²^*, Emma Kolesar³^*, Mehran Anvari, MD³^*, Maria Tiboni, MD³^*, James D. Douketis, MD^4,5^* and Mark A. Crowther, MD, MSc, FRCPC⁶

¹McMaster University, Hamilton, ON, Canada
²Tan Tock Seng Hospital, Tan Tock Seng, Singapore
³St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada
⁴St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
⁵Department of Medicine, McMaster University, Hamilton, ON, Canada
⁶St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada

1131

Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD^*, Luise Tittl, B.Sc.^*, Katharina Daschkow^* and Jan Beyer-Westendorf, MD

Vascular Medicine, Dresden University Hospital, Dresden, Germany

1132

Blood Hypercoagulation Assessed with Thrombodynamics Test Predicts Postoperative Venous Thrombosis in Patients at High Risk

Kirill Lobastov, PhD^1,2,3^*, Galina Dementieva¹^*, Natalia Soshitova, PhD⁴^*, Victor Barinov, PhD, MD^1,3^*, Leonid Laberko, PhD, MD^1,2^*, Grigory Rodoman^1,2^* and Valeriy Boyarintsev³^*

¹Pirogovs Russian National Research Medical University, Moscow, Russia
²Moscow Clinical Hospital no.24, Moscow, Russia
³Clinical Hospital no.1 of the President's Administration of Russian Federation, Moscow, Russia
⁴HemaCore Company, Moscow, Russia

1133

Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome

Paul Kunk, MD, B. Gail Macik, MD and Melissa Rice, MD^*

University of Virginia, Charlottesville, VA

1134

Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial

Hulda M. Jensdottir, BS¹^*, Brynjar Vidarsson, MD¹^*, Brynja R. Gudmundsdottir, MS¹^*, Alma R. Oskarsdottir, BS¹^*, Olafur S. Indridason, MD, MPH¹^*, David O. Arnar, MD, PhD¹^*, Einar S. Bjornsson, MD, PhD^1,2^*, Magnus K. Magnusson, MD^1,2^*, Sigrun H. Lund, PhD²^*, Charles W. Francis, MD³ and Pall T. Onundarson, MD^1,2

1135

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Leeds Janet, Ph.D.¹^*, Genmin Lu, PhD¹^*, John T. Curnutte, MD, PhD¹, Pamela B. Conley, PhD¹ and Jaap W. Mandema, Ph.D.²^*

¹Portola Pharmaceuticals, Inc., South San Francisco, CA
²Quantitative Solutions, Menlo Park, CA

1136

A Comprehensive Review of IVC Filters in a Community Tertiary Center

Benjamin Parsons, DO¹, Peter Polewski, MD²^*, Angela Smith, MA³^*, Kurt Ziegelbein, MD⁴^*, Andrew Horstman, PA-C²^*, Ezana Azene, MD, Ph.D⁴^*, Shannon Brozak, PA-C⁵^*, Mason Fisher, MD⁵^* and Paul Escher³^*

¹Division of Hematology/Oncology, Gundersen Health System, La Crosse, WI
²Gundersen Health System, La Crosse, WI
³Gundersen Lutheran Medical Foundation, La Crosse, WI
⁴Interventional Radiology, Gundersen Health System, La Crosse, WI
⁵Surgery, Gundersen Health System, La Crosse, WI

1137

Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review

Deborah M. Siegal, MD, MSc¹, Ron Movilla²^*, Reda Siddiqui¹^*, Rebecca Barty, MLT, CTRC¹^*, Mark A. Crowther, MD, MSc, FRCPC³ and Nancy M Heddle, MSc¹

¹McMaster University, Hamilton, ON, Canada
²McMaster Transfusion Medicine Research Program, McMaster University, Hamilton, ON, Canada
³St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada

See more of: Antithrombotic Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

332.P1.39 332. Antithrombotic Therapy: Poster I